((自动化翻译由路透提供,请见免责声明 )) Blake Brittain
路透10月22日 - 安进公司发言人说,在美国上诉法院周二作出有利于安进公司的裁决后,安进公司 将推出其生物仿制药Regeneron公司 的大片眼部护理药Eylea。
美国联邦巡回上诉法院驳回了再生元提出的在对西弗吉尼亚州一宗专利案中安进公司胜诉的相关裁决提起上诉期间暂时阻止Eylea上市的请求。
Regeneron公司的发言人没有立即回应就这一判决发表评论的请求。2023 年,Eylea 将为 Regeneron 带来 58.9 亿美元的美国销售额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.